Updates in Multiple Myeloma and the Role of CAR-T Therapy

CAR-T therapy has become an increasingly important treatment option for multiple myeloma patients. The US myeloma CAR-T consortium has conducted retrospective analyses to evaluate real-world outcomes of CAR-T therapy. Results indicate that response rates for CAR-T in patients who have had prior B CMA therapies are comparable to those who are B CMA naive, with an 88% response rate. However, patients who received Ida cell after prior B CMA therapies had lower response rates, suggesting the possibility of T cell exhaustion or B CMA antigen-related factors. Additionally, patients who waited six months between B CMA therapies showed better progression-free survival (PFS). These findings highlight the need for optimized sequencing of therapies and the importance of considering patient-specific factors in CAR-T treatment decisions.